SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (944)6/4/1997 1:26:00 AM
From: Roger Cranwill   of 1762
 
Brad-
Comparisons of duration of response were discussed at the annual meeting. The standard regimen of chemotherapy has a shorter duration of response with each relapse by the patient, which has been a major problem with chemo. However, it appears (so far) that C2B8 doesn't fall into this pattern-I say so far, because the people in remission with C2B8 haven't needed that many retreatments! Roger
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News